Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry

Ahmed, Hytham M.; Wahbi, Abdel‐Aziz M.; Elmongy, Hatem; Ahmad, A.L.; Koyi, Hirsh; Brandén, Eva; Abdel‐Rehim, Mohamed

doi:10.1155/2021/8845139

Cited by 10 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the use of a recent extraction methodology, Microextraction by Packed Sorbent (MEPS), has been shown to be effective in this matrix for PK/PD studies [20,27]. MEPS technology consists of Solid-Phase Extraction (SPE) miniaturization with a compacted bed (1-2 mg).…”

Section: Introductionmentioning

confidence: 99%

CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid

et al. 2022

View full text Add to dashboard Cite

Polymorphisms in CYP2C9 can significantly interfere with the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen. The present research aimed to study the PK/PD parameters of naproxen and its metabolite, 6-O-desmethylnaproxen, associated with allelic variations of CYP2C9. In our study, a rapid, selective, and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) method was developed and validated for the determination of naproxen and its main metabolite, 6-O-desmethylnaproxen, in oral fluid. Naproxen and its main metabolite were separated using a Shim-Pack XR-ODS 75L × 2.0 column and C18 pre-column at 40 °C using a mixture of methanol and 10 mM ammonium acetate (70:30, v/v), with an injection flow of 0.3 mL/min. The total analytical run time was 3 min. The volunteers, previously genotyped for CYP2C9 (16 ancestral—CYP2C9 *1 and 12 with the presence of polymorphism—CYP2C9 *2 or *3), had their oral fluids collected sequentially before and after taking a naproxen tablet (500 mg) at the following times: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6 8, 11, 24, 48, 72 and 96 h. Significant differences in the PK parameters (* p < 0.05) of naproxen in the oral fluid were: Vd/F (L): 98.86 (55.58–322.07) and 380.22 (261.84–1097.99); Kel (1/h): 0.84 (0.69–1.34) and 1.86 (1.09–4.06), in ancestral and mutated CYP2C9 *2 and/or *3, respectively. For 6-O-desmethylnaproxen, no PK parameters were significantly different between groups. The analysis of prostaglandin E2 (PGE2) proved to be effective and sensitive for PD parameters analysis and showed higher levels in the mutated group (p < 0.05). Both naproxen and its main metabolite, 6-O-desmethylnaproxen, and PGE2 in oral fluid can be effectively quantified using LC-MS/MS after a 500 mg oral dose of naproxen. Our method proved to be effective and sensitive to determine the lower limit of quantification of naproxen and its metabolite, 6-O-desmethylnaproxen, in oral fluid (2.4 ng/mL). All validation data, such as accuracy, precision, and repeatability intra- and inter-assay, were less than 15%. Allelic variations of CYP2C9 may be considered relevant in the PK of naproxen and its main metabolite, 6-O-desmethylnaproxen.

show abstract

Section: Introductionmentioning

confidence: 99%

CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid

et al. 2022

View full text Add to dashboard Cite

show abstract

“…0.1 and 0.4 ng/mL (calculated limits) for both samples and compounds 25-600 ng/mL (plasma) and 25-300 ng/mL (oral fluid) for both compounds [22] ESI: electrospray ionization; HPLC-DAD: high-performance liquid chromatography-diode array detection; HPLC-UV-FL: liquid chromatography-sequential spectrophotometric and spectrofluorimetric detection; HPLC-FLD: high-performance liquid chromatography-fluorescence detection; LC-MS/MS: liquid chromatography-tandem mass spectrometry; LOD: limit of detection; LOQ: limit of quantitation; MEPS: microextraction by packed sorbent; n.a. : not available; RACNT: restricted access carbon nanotubes; UHPLC-MS/MS: ultra-high liquid chromatography-tandem mass spectrometry; VAMS: volumetric absorptive microsampling.…”

Section: Lc-ms/ms (Esi)mentioning

confidence: 92%

Solid Phase-Based Microextraction Techniques in Therapeutic Drug Monitoring

et al. 2023

View full text Add to dashboard Cite

Therapeutic drug monitoring is an established practice for a small group of drugs, particularly those presenting narrow therapeutic windows, for which there is a direct relationship between concentration and pharmacological effects at the site of action. Drug concentrations in biological fluids are used, in addition to other clinical observation measures, to assess the patient’s status, since they are the support for therapy individualization and allow assessing adherence to therapy. Monitoring these drug classes is of great importance, as it minimizes the risk of medical interactions, as well as toxic effects. In addition, the quantification of these drugs through routine toxicological tests and the development of new monitoring methodologies are extremely relevant for public health and for the well-being of the patient, and it has implications in clinical and forensic situations. In this sense, the use of new extraction procedures that employ smaller volumes of sample and organic solvents, therefore considered miniaturized and green techniques, is of great interest in this field. From these, the use of fabric-phase extractions seems appealing. Noteworthy is the fact that SPME, which was the first of these miniaturized approaches to be used in the early ‘90s, is still the most used solventless procedure, providing solid and sound results. The main goal of this paper is to perform a critical review of sample preparation techniques based on solid-phase microextraction for drug detection in therapeutic monitoring situations.

show abstract

“…Tako je tehnikom MEPS unaprijeđeno terapijsko praćenje koncentracije raznovrsnih lijekova, poput opoidnih, 45 antiepileptičkih 46 i antikonvulzivnih lijekova, 47,48 kemoterapeutika, 49,50 hipolipemika 51 te inhibitora protonske pumpe. 52 Nadalje, tehnikom MEPS postignuta je iznimna osjetljivost (LOD vrijednosti i do 0,12 µg l −1 ) za tumorske biomarkere, čime je omogućeno ranije postavljanje dijagnoze te posljedično bolji ishodi liječenja pacijenata. 53,54 Tehnika MEPS vrlo je pogodna za rukovanje s malim volumenima uzoraka krvi (25-50 µl), što ju čini prikladnom tehnikom u pretkliničkim farmakokinetičkim studijama jer doprinosi poštivanju etičkih načela o upotrebi laboratorijskih životinja u biomedicinskim istraživanjima.…”

Section: Disprezivna Mikroekstrakcija čVrstom Fazomunclassified

Mikroekstrakcija čvrstom fazom – inovativni pristup u bioanalitičkim istraživanjima

Mornar

Marinac-Anđić

Klarić

et al. 2022

Kemija U Industriji

View full text Add to dashboard Cite

In last three decades, the solid-phase microextraction technology has brought significant progress in bioanalytical research due to the versatility of this fast and solvent-free approach to biological sample preparation. It has been widely used in combination with various analytical instrumentation, even if most of the work has been done by coupling the extraction technique with liquid or gas chromatography. This review focuses on the new developments and advances in solid-phase microextraction-based techniques. Furthermore, some interesting, new innovations that fail to go beyond academic research are also reported.

show abstract

Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry

Cited by 10 publications

References 35 publications

CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid

CYP2C9 Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid

Solid Phase-Based Microextraction Techniques in Therapeutic Drug Monitoring

Mikroekstrakcija čvrstom fazom – inovativni pristup u bioanalitičkim istraživanjima

Contact Info

Product

Resources

About